OTCM
ALID
Market cap0kUSD
May 27, Last price
0.00USD
Name
Allied Corp
Chart & Performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Allied Corp. (ALID) specializes in the research, development, and production of cannabinoid health solutions, primarily operating in the United States. The company markets a diverse portfolio of natural health products derived from hemp under various brands. Its "Tactical Relief" line features items such as Liberty, a CBD tincture; Tactical Hydration, a CBD-infused electrolyte beverage; FIZZ Tablets designed for water bottles; Battle Balm, a CBD roll-on formulated for activity-related aches and pains; and Quick Hit, a CBD gummy. Similarly, the "Equilibrium Bio" brand encompasses Hydrosport CBD Drink, an electrolyte beverage fortified with sodium citrate; Hydrosport Tincture, a CBD tincture enhanced with specific terpene profiles; FIZZ Tablets for customizable drinks; Sport Rub, a CBD topical for post-activity muscle relief; and Quick Hit, a CBD gummy enriched with vitamin B12. Additionally, Allied Corp. distributes a specialized skincare line under its "MaXXa" brand. This collection features Skin Structure, a facial formula for enhancing skin radiance and youthfulness; Eye Recover, designed to protect delicate eye skin from free radicals and sun damage; Glossy Lip Recover, which moisturizes and nourishes lips; Skin Designer, stimulating cell regeneration and minimizing age spots; Vitamin Absolute, a hydrating facial oil; and Absolute Recover, a formulation for direct delivery of bioactive compounds to address inflammation, pain, and other skin ailments. Beyond its consumer product portfolio, Allied Corp. is also engaged in pharmaceutical development, with ALID 10 and ALID 11, experimental drug candidates, currently in Phase I clinical trials for the treatment of post-traumatic stress disorder (PTSD). Established in 2013, Allied Corp. maintains its corporate headquarters in Kelowna, Canada.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|
| 2023‑08 | 2022‑08 | 2021‑08 | 2020‑08 | 2019‑03 | 2018‑03 | 2017‑03 | |
| Income | |||||||
Revenues | |||||||
Cost of revenue | |||||||
Unusual Expense (Income) | |||||||
NOPBT | |||||||
NOPBT Margin | |||||||
Operating Taxes | |||||||
Tax Rate | |||||||
NOPAT | |||||||
Net income | |||||||
Dividends | |||||||
Dividend yield | |||||||
Proceeds from repurchase of equity | |||||||
BB yield | |||||||
| Debt | |||||||
Debt current | |||||||
Long-term debt | |||||||
Deferred revenue | |||||||
Other long-term liabilities | |||||||
Net debt | |||||||
| Cash flow | |||||||
Cash from operating activities | |||||||
CAPEX | |||||||
Cash from investing activities | |||||||
Cash from financing activities | |||||||
FCF | |||||||
| Balance | |||||||
Cash | |||||||
Long term investments | |||||||
Excess cash | |||||||
Stockholders' equity | |||||||
Invested Capital | |||||||
ROIC | |||||||
ROCE | |||||||
| EV | |||||||
Common stock shares outstanding | |||||||
Price | |||||||
Market cap | |||||||
EV | |||||||
EBITDA | |||||||
EV/EBITDA | |||||||
Interest | |||||||
Interest/NOPBT | |||||||